LifeMD, Inc. Common Stock Reports Strong Q4 and Full Year Performance

LifeMD, Inc. Common Stock showcased impressive growth in its fourth quarter and full-year results, emphasizing the company's solid positioning in the telehealth space. The company ended 2025 with over 322,000 active subscribers and a robust balance sheet featuring $37 million in cash and no debt. With significant strides in weight management and women's health, LifeMD is well-equipped to capitalize on growing market opportunities. This article delves into the company's financial performance, strategic initiatives, and future outlook following its recent earnings call.

Financial Performance

LifeMD reported a 25% increase in total revenue for 2025, reaching $194.1 million compared to the previous year. The fourth quarter revenue also saw a 4% year-over-year growth, totaling $46.9 million. Key financial metrics include:

• Active subscribers: Increased by 16% year-over-year to nearly 323,000.
• Gross profit: Grew by 25% to $166.3 million.
• Gross margin: For Q4, gross margin stood at 87.1%, an increase of 570 basis points compared to the prior year.
• Net income: The company reported a GAAP net income of $19 million for Q4, translating to $0.41 per share, while the full year reflected a net income of $11.2 million or $0.25 per share.
• Adjusted EBITDA: Q4 saw an adjusted EBITDA of $4.8 million, up from $1.1 million in the prior year.

LifeMD’s ability to reduce customer acquisition costs (CACs) while increasing patient signups is noteworthy. The company onboarded approximately 1,200 new patients per day, reflecting the effectiveness of its marketing strategies.

Strategic Initiatives

LifeMD's strategic focus on expanding its service offerings is evident through several key initiatives:

Weight Management Expansion

The company successfully launched the Oral Wegovy in collaboration with Novo Nordisk, enhancing access for patients preferring oral medication. This initiative has resulted in record patient acquisition volumes, with approximately 700 new signups daily for the weight management program alone. LifeMD’s efforts in this sector are significant given that over 100 million Americans are clinically eligible for GLP-1 therapy.

Women's Health Initiative

LifeMD has committed substantial resources to build a comprehensive women's health offering. The acquisition of Optimal Human Health and partnerships with recognized experts like Dr. Tara Scott position LifeMD to address the pressing needs in women's hormonal and bone health. The company aims to launch insurance support for its offerings and expects this sector to contribute meaningfully to revenue in 2026.

Men's Health and Pharmacy Operations

The Rex MD brand has also returned to growth with approximately 215,000 active patients. LifeMD plans to expand its offerings beyond sexual health into other categories, including insomnia and dermatology. The company's pharmacy operations, licensed in all 50 states, are processing around 20,000 prescriptions per month, providing a solid foundation for profitability and patient engagement.

AI-Driven Healthcare

LifeMD is prioritizing the integration of artificial intelligence (AI) in its operations. The company is developing an AI Clinical Decision Support tool to enhance patient care and streamline operations. This initiative aims to improve patient outcomes and operational efficiencies, further solidifying LifeMD's competitive edge in the telehealth market.

Future Outlook

Looking ahead, LifeMD has provided optimistic guidance for 2026, projecting revenue between $220 million and $230 million and an adjusted EBITDA of $12 million to $17 million. Key drivers for this growth include:

• Subscriber Growth: Continued expansion in weight management and women's health is expected, with the company's marketing investments anticipated to yield significant returns in the latter half of 2026.
• Insurance Coverage: With plans to expand its benefits infrastructure to cover over 220 million lives, LifeMD is poised to enhance patient retention and lower customer acquisition costs.
• Product Diversification: The launch of new men's health offerings and compounded medications will further diversify the revenue streams and strengthen market positioning.

Management is clear that the investments made in patient acquisition reflect a long-term growth strategy, with LifeMD expected to return to adjusted EBITDA profitability in the second quarter of 2026.

Conclusion

In summary, LifeMD, Inc. Common Stock demonstrated a robust performance in 2025, bolstered by strong subscriber growth and strategic initiatives across its service offerings. The company's focus on weight management and women's health, combined with a solid financial foundation and ambitious growth plans, places it in an advantageous position within the telehealth landscape. Investors can be optimistic about LifeMD's future potential as it navigates the evolving healthcare market and capitalizes on emerging opportunities. With a strategic commitment to innovation and patient care, LifeMD is set to enhance its market position and deliver value to its stakeholders in the coming years.